Department of Ophthalmology, 4th Military Clinical Hospital with Polyclinic, Weigla 5, 50-981 Wroclaw, Poland.
Department of Ophthalmology and Ocular Oncology, the Jagiellonian University, Medical College, Kopernika 38, 31-501 Krakow, Poland.
Folia Histochem Cytobiol. 2020;58(2):108-116. doi: 10.5603/FHC.a2020.0017. Epub 2020 Jun 30.
Uveal melanoma (UM) is the most common primary eye tumour in adults. Distant metastases are seen in 50% of cases regardless of treatment, which contributes to high mortality rates. Polo-like kinase-1 (PLK-1) is a protein regulator of mitotic entry and cytokinesis. Increased PLK-1 expression has been shown in different tumours, which makes its inhibition a potential treatment target. To date, no study has been published to discuss the prognostic role of PLK-1 expression in patients with uveal melanoma.
We assessed by immunohistochemistry PLK-1 expression in uveal melanoma cells collected in 158 patients treated by primary enucleation. We determined the correlation between PLK-1 levels evaluated by the immunoreactivity scale (IRS) method and detailed clinical as well as histological parameters. Additionally, we determined the association between PLK-1 expression levels and long-term prognosis.
Elevated PLK-1 expression in tumour cells, defined as IRS > 2, was observed in 70% (111/158) of cases, whereas low expression or no expression was seen in the remaining 30% (47/158) of patients. There was a significant correlation between low PLK-1 expression and a higher clinical tumour stage (pT, p = 0.04) as well as a higher AJCC prognostic stage group (p = 0.037). We observed an inverse correlation between PLK-1 expression and tumour cell pigment content (p = 0.0019). There was no correlation between PLK-1 expression and other histological parameters such as mitotic rate or histological subtype. The Kaplan-Meier's analysis demonstrated that low PLK-1 expression was associated with significantly reduced overall survival (p = 0.0058). A similar trend, albeit not significant, was observed for disease-free survival (p = 0.088).
Downregulated PLK-1 expression is a negative prognostic factor in uveal melanoma. It warrants further, multicentre research on prognostic role of PLK-1 expression and possibility of PLK-1 inhibition in uveal melanoma.
葡萄膜黑色素瘤(UM)是成年人中最常见的原发性眼部肿瘤。无论治疗与否,50%的病例都会出现远处转移,这导致了高死亡率。Polo 样激酶-1(PLK-1)是一种有丝分裂进入和胞质分裂的蛋白调节因子。在不同的肿瘤中已经显示出 PLK-1 表达增加,这使其抑制成为潜在的治疗靶点。迄今为止,尚无研究探讨 PLK-1 表达在葡萄膜黑色素瘤患者中的预后作用。
我们通过免疫组织化学法评估了 158 例接受初次眼球摘除术治疗的葡萄膜黑色素瘤患者的肿瘤细胞中 PLK-1 的表达。我们通过免疫反应性评分(IRS)方法评估了 PLK-1 水平与详细的临床和组织学参数之间的相关性。此外,我们还确定了 PLK-1 表达水平与长期预后之间的关联。
在 70%(111/158)的病例中观察到肿瘤细胞中 PLK-1 表达升高(IRS>2),而在其余 30%(47/158)的患者中表达较低或无表达。低 PLK-1 表达与较高的临床肿瘤分期(pT,p=0.04)和较高的 AJCC 预后分期组(p=0.037)显著相关。我们观察到 PLK-1 表达与肿瘤细胞色素含量之间呈负相关(p=0.0019)。PLK-1 表达与有丝分裂率或组织学亚型等其他组织学参数之间无相关性。Kaplan-Meier 分析表明,低 PLK-1 表达与总生存率显著降低相关(p=0.0058)。无疾病生存率也有类似的趋势,但无统计学意义(p=0.088)。
下调的 PLK-1 表达是葡萄膜黑色素瘤的一个负预后因素。它需要进一步的多中心研究,以探讨 PLK-1 表达的预后作用以及在葡萄膜黑色素瘤中抑制 PLK-1 的可能性。